South East Asia Business Awards 2026 | 7 Asia is home to the world’s fastest growing and most promising anti-aging market, projected to grow at a CAGR of 11.25% from 2026 to 2035, reaching USD 67.03 billion by 2035. Estimations that one in every 11 people in Asia will be over 65 years of age by 2050, combined with rising health awareness across the continent, presents anti-aging as a prosperous blue ocean market with much opportunity for commercial success. SDAI Limited is one biotechnology company traversing this new space, leading the charge in anti-aging and healthy longevity. CEO Jessica Liu Ting told us more below. “Science Guards Life, Technology Empowers Longevity.” SDAI is a new entrant rapidly rising in Asia’s anti-aging and longevity health management sector. Listed on the SGXST Catalist Board, the biotechnology company has set out to reshape the landscape of Asia’s anti-aging industry with the dual-engine drive of “digital + biological”. Rather than simply adding new products and services to the market, SDAI intends to redefine standards for healthy longevity in Asia. In a fiercely competitive market, SDAI has pioneered an entirely new commercial category: biological age management. It understands that genetic and lifestyle differences mean that anti-aging solutions developed for Western populations may not be as effective for Asian populations. Thus, it has capitalised on this underserved market by building an anti-aging product system designed exclusively for Asian consumers, integrating millennia of traditional Chinese herbal medicine with cutting-edge life science technology. “We are most proud of this perfect integration of Eastern and Western wisdom,” Jessica told us. “We use modern scientific methods to standardise and quantify the efficacy of traditional Chinese herbs, breathing new commercial value into ancient wisdom while making our products more suitable for the physiological needs and cultural identity of Asian consumers.” Building on to this unique perspective, SDAI has established an end-toend commercial service grounded in “assessment-intervention-management”. This comprises epigenetic and metabolic biomarker testing based on an exclusive Asian population database to accurately quantify true aging levels. This is complemented by lifetime health management, delivered through one-stop concierge services spanning preventative screening to postintervention effect tracking. The “assessment-intervention-management” service also includes a diversified product system of personalised anti-aging intervention programmes, covering scientifically formulated nutritional supplements and cutting-edge life science therapies. SDAI has also developed an intelligent digital health platform that allows for the secure storage and real-time dynamic management of health data, powered by AI and blockchain technology. At its core, SDAI always places consumer health and quality of life above commercial interests. Grounded in scientific spirit, the team adheres to medical ethics and the highest international standards in biotechnology. All product efficacy claims must be supported by at least two independent double-blind clinical trials, with results published in authoritative international journals. SDAI rejects vague expressions and requires all promotional materials to clearly cite data sources, building brand trust with hard strength. The market is currently plagued by mixed quality and rampant pseudoscience, with consumers urgently seeking credible, effective anti-aging brands. This significant pain point provides SDAI with great opportunity for growth. “Our principles have allowed us to stand out in an anti-aging market flooded with false advertising, establishing a brand mindshare of ‘scientific, credible, and safe’,” said Jessica. “Trust is the most precious intangible asset in the anti-aging industry, and the fundamental guarantee for our long-term growth.” Over the next three years, SDAI will focus on three core strategic goals that will propel the company from “benchmark new entrant” to “industry leader”. First, the team will drive SDAI’s market position, with plans to fully occupy Asia’s biological age management track, capture a share of over 15% in core target markets, achieve exponential growth in revenue and profits, and ultimately position SDAI as the undisputed leading anti-aging brand in Asia. Following this is technological breakthrough, which will see SDAI deepening its cutting-edge life science pipeline, advancing its first innovative therapy for age-related diseases to late-stage clinical trials, and building a comprehensive product matrix covering small molecules, macromolecules, and cell therapies. Finally, SDAI will enter ecosystem construction, partnering with the world’s top research institutions, healthcare providers, and insurance companies to build Asia’s first integrated longevity health ecosystem, upgrading from a single product provider to a fullindustry-chain platform enterprise. “Standing at the forefront of Asia’s trilliondollar longevity economy, SDAI is entering an explosive growth period,” Jessica concluded. “We firmly believe that healthy longevity is humanity’s eternal pursuit, and SDAI is turning this pursuit into enormous commercial value. We sincerely invite global investors and partners to join us in tapping into Asia’s longevity blue ocean and writing the next golden decade of the health industry together.” Contact: Jessica Liu Ting Company: SDAI Limited Web Address: www.sdai.com.sg Best Biotechnology Healthcare Solutions Development 2026 – Asia Pacific
RkJQdWJsaXNoZXIy MTUyMDQwMA==